國泰君安(601211.SH)完成發行40億元公司債券 最終票面利率為3.05%
格隆匯3月23日丨國泰君安(601211.SH)公佈,根據發行公告,公司公開發行2020年公司債券(第二期)(“本期債券”)發行規模為不超過人民幣40億元(含40億元),發行價格為每張人民幣100元,採用網下面向合格投資者簿記建檔的方式發行。
本期債券發行工作已於2020年3月23日結束,品種一的實際發行規模40億元,最終票面利率為3.05%;品種二未實際發行。其中,發行人的關聯方上海浦東發展銀行股份有限公司參與了本期債券品種一的認購,最終獲配金額為5000萬元,佔本期債券發行規模的1.25%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.